KRAS and cancer: In the explorative analysis, assessing the association between response to sotorasib and the presence of previously described co-occurring mutations (STK11, KEAP1, and TP53), which define three subgroups of KRAS mutant cancers with different biology and response to treatment (33), sotorasib showed efficacy in all subgroups, with a lower percentage of response in patients with KEAP1 mutated tumors, although this was not statistically significant.